ArticleThe Journal of clinical investigation2001
Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis.
Article in The Journal of clinical investigation, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 192 citations in OpenAlex.
- Genetically engineered cellular nanoparticles for biomedical applications.Biomaterials · 2023Review
- Review
- Preclinical models of arthritis for studying immunotherapy and immune tolerance.Annals of the rheumatic diseases · 2021Review
- Lymph Node Stromal Cells From Different Draining Areas Distinctly Regulate the Development of Chronic Intestinal Inflammation.Frontiers in immunology · 2020Article
- Dendritic Cell-Mediated Th2 Immunity and Immune Disorders.International journal of molecular sciences · 2019Review
- Tolerising cellular therapies: what is their promise for autoimmune disease?Annals of the rheumatic diseases · 2019Review
- BATF regulates collagen-induced arthritis by regulating T helper cell differentiation.Arthritis research & therapy · 2018Article
- Systemic treatment with resveratrol reduces the progression of experimental periodontitis and arthritis in rats.PloS one · 2018Article
- The Protective Effect ofBioMed research international · 2017Article
- Amelioration of collagen-induced arthritis using antigen-loaded dendritic cells modified with NF-κB decoy oligodeoxynucleotides.Drug design, development and therapy · 2017Article
- T helper 2 and T follicular helper cells: Regulation and function of interleukin-4.Cytokine & growth factor reviews · 2016Review
- Induction of tolerance against the arthritogenic antigen with type-II collagen peptide-linked soluble MHC class II molecules.BMB reports · 2016Article
- Generation of Tolerogenic Dendritic Cells and Their Therapeutic Applications.Immune network · 2016Review
- Dexamethasone and Monophosphoryl Lipid A-Modulated Dendritic Cells Promote Antigen-Specific Tolerogenic Properties on Naive and Memory CD4Frontiers in immunology · 2016Article
- A combination dual-sized microparticle system modulates dendritic cells and prevents type 1 diabetes in prediabetic NOD mice.Clinical immunology (Orlando, Fla.) · 2015Article
- Loss of SH3 domain-binding protein 2 function suppresses bone destruction in tumor necrosis factor-driven and collagen-induced arthritis in mice.Arthritis & rheumatology (Hoboken, N.J.) · 2015Article
- DC-Based Immunotherapy Combined with Low-Dose Methotrexate Effective in the Treatment of Advanced CIA in Mice.Journal of immunology research · 2015Article
- SH3BP2 gain-of-function mutation exacerbates inflammation and bone loss in a murine collagen-induced arthritis model.PloS one · 2014Article
- The roles of IFN-γ versus IL-17 in pathogenic effects of human Th17 cells on synovial fibroblasts.Modern rheumatology · 2013Article
- IL-4, JAK-STAT signaling, and pain.JAK-STAT · 2013Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Dendritic cells (DCs) are specialized antigen-presenting cells that migrate from the periphery to lymphoid tissues, where they activate and regulate T cells. Genetic modification of DCs to express immunoregulatory molecules would provide a new immunotherapeutic strategy for autoimmune and other diseases. We have engineered bone marrow-derived DCs that express IL-4 and tested the ability of these cells to control murine collagen-induced arthritis (CIA), a model for rheumatoid arthritis in which Th1 cells play a critical role. IL-4-transduced DCs inhibited Th1 responses to collagen type II in vitro. A single injection of IL-4-transduced DCs reduced the incidence and severity of CIA and suppressed established Th1 responses and associated humoral responses, despite only transient persistence of injected DCs in the spleen. In contrast, control DCs and IL-4-transduced T cells or fibroblastic cells failed to alter the course of the disease. The functional effects correlated well with the differential efficiency of DC migration from various sites of injection to lymphoid organs, especially the spleen. The ability of splenic T cells to produce IL-4 in response to anti-CD3 was enhanced after the administration of IL-4-transduced DCS: These results support the feasibility of using genetically modified DCs for the treatment of autoimmune disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.